
A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atheroscle
Keywords: TMed, Translational Medicine; MOA, mechanism of actionTranslational Medicine; HDL; CETP; Torcetrapib, Atherosclerosis